BRIEF published on 11/25/2025 at 18:38, 9 days 12 hours ago ABIONYX Pharma publie ses prévisions d'activité pour le troisième trimestre 2025 Mise À Jour Financière Revenu ABIONYX Pharma 3e Trimestre 2025 Recherche Sur La Septicémie
BRIEF published on 11/25/2025 at 18:38, 9 days 12 hours ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 9 days 12 hours ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 9 days 12 hours ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 23 days ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
BRIEF published on 11/12/2025 at 07:05, 23 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
PRESS RELEASE published on 11/12/2025 at 07:00, 23 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 1 month 14 days ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 1 month 14 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 1 month 14 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
Published on 12/05/2025 at 02:35, 4 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 27 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 12 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 27 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 42 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
